Tag Archives: Canada

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Posted in Op-Ed, pricing | Also tagged , , , | Leave a comment

Those Amazing 'Gold Plated, Cadillac Care' Drug Programs

by Tom Norton Not too many years ago, while employed by one of America’s leading Rx manufacturers, I remember stepping up to a retail drug store counter to pick up a prescription.  As the pharmacist handed me my script, he said, “Wow.  I don’t know what kind of health insurance you have, but I have […]
Posted in FDA, Global, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Posted in Global, healthcare, IP, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Also tagged , , , , | Leave a comment

Are US and Canadian Rx Policies Converging?

by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.  To say that this is a critical concern for the […]
Posted in Global, Guest Blog, healthcare, Legal, Market Access, Strategy | Also tagged , , , , , | Leave a comment

Merck to Close Eight Plants

Image by Getty Images via @daylife Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.” Taking a page out of […]
Posted in Strategy | Also tagged , , , , , , | 3 Comments
  • Categories

  • Meta